An Age-Dependent Pharmacokinetic Study of Intravenous and Oral Mycophenolate Mofetil in Combination with Tacrolimus for GVHD Prophylaxis in Pediatric Allogeneic Stem Cell Transplantation Recipients

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 333-343

  Bhatia, Monica ^a   Militano, Olga ^a   Jin, Zhezhen ^a   Figurski, Michal ^b   Shaw, Leslie ^b   Moore, Virginia ^a   Morris, Erin ^a   Tallamy, Bradford ^a   van deVen, Carmella ^a   Ayello, Janet ^a   Baxter Lowe, LeeAnn ^c   Satwani, Prakash ^a   George, Diane ^a   Bradley, M Brigid ^a   Garvin, James ^a   Cairo, Mitchell S ^a  

^a Howard Hughes Medical Institute   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AlloSCT; MMF; Pediatric; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADOLESCENT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CHILD; CHILD CARE; CHIMERA; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTRITIS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MYELOABLATIVE CONDITIONING; NAUSEA; NEPHROTOXICITY; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRESCHOOL CHILD; SCHOOL CHILD; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADOLESCENT; AGING; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KAPLAN-MEIERS ESTIMATE; MALE; MYCOPHENOLIC ACID; TACROLIMUS; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 75749085170     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.10.007     Document Type: Article

References (43)

1. Cairo M., and Heslop H. Pediatric blood and marrow transplantation: state of the science. Bone Marrow Transplant 41 (2008) 97
2. Chao N. Graft Versus Host Disease (1999), R.G. Landes Co, Austin, TX
3. Ferrara J.L., Levy R., and Chao N.J. Pathophysiologic mechanisms of acute graft-vs.-host disease. Biol Blood Marrow Transplant 5 (1999) 347-356
4. Jacobsohn D.A. Acute graft-versus-host disease in children. Bone Marrow Transplant 41 (2008) 215-221
5. Mrsic M., Labar B., Bogdanic V., et al. Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 6 (1990) 137-141
6. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314 (1986) 729-735
7. Jensen C.W., Flechner S.M., Van Buren C.T., et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 43 (1987) 263-270
8. Lazarus H.M., Coccia P.F., Herzig R.H., et al. Incidence of acute graft-versus-host disease with and without methotrexate prophylaxis in allogeneic bone marrow transplant patients. Blood 64 (1984) 215-220
9. Thompson C.B., June C.H., Sullivan K.M., and Thomas E.D. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 2 (1984) 1116-1120
10. Lin C.S., Boltz R.C., Siekierka J.J., and Sigal N.H. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. Cell Immunol 133 (1991) 269-284
11. Peters D.H., Fitton A., Plosker G.L., and Faulds D. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 46 (1993) 746-794
12. Hiraoka A., Ohashi Y., Okamoto S., et al. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 28 (2001) 181-185
13. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
14. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
15. Basara N., Blau W.I., Romer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 22 (1998) 61-65
16. Bornhauser M., Schuler U., Porksen G., et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 67 (1999) 499-504
17. Dvorak C.C., Callard E., and Agarwal R. Use of intravenous mycophenolate mofetil for graft-versus-host disease prophylaxis in an allogeneic hematopoietic stem cell transplant recipient with an allergic reaction to cyclosporine and tacrolimus. Bone Marrow Transplant 38 (2006) 253-254
18. Haentzschel I., Freiberg-Richter J., Platzbecker U., et al. Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplant 42 (2008) 113-120
19. Mohty M., de Lavallade H., Faucher C., et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 527-530
20. Osunkwo I., Bessmertny O., Harrison L., et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 10 (2004) 246-258
21. Shapira M.Y., Hirshfeld E., Weiss L., et al. Mycophenolate mofetil does not suppress the graft-versus-leukemia effect or the activity of lymphokine-activated killer (LAK) cells in a murine model. Cancer Immunol Immunother 54 (2005) 383-388
22. Glucksberg H., Storb R., Fefer A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 18 (1974) 295-304
23. Tsina I., Chu F., Hama K., et al. Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr 675 (1996) 119-129
24. Figurski M., Korecka M., Fields L., Waligorska T., and Shaw L. HPLC-MS/MS method for simultaneous quantification of total or free fraction of mycophenolic acid and its glucuronide metabolites. Ther Drug Monit 29 (2007) 511-512
25. Gibaldi M. Biopharmaceutics and Clinical Pharmacokinetics. Biopharmaceutics and Clinical Pharmacokinetics (1984), Lea and Febiger, Philadelphia, PA 315-316
26. Jacobson P., Huang J., Rydholm N., et al. Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). J Clin Pharmacol 48 (2008) 485-494
27. Nash R.A., Johnston L., Parker P., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11 (2005) 495-505
28. Papadimitriou J.C., Cangro C.B., Lustberg A., et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol 11 (2003) 295-302
29. Baron F., Sandmaier B.M., Storer B.E., et al. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. Biol Blood Marrow Transplant 13 (2007) 1041-1048
30. Giaccone L., McCune J.S., Maris M.B., et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 106 (2005) 4381-4388
31. Jenke A., Renner U., Richte M., et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 15 (2001) 176-184
32. Bullingham R., Monroe S., Nicholls A., and Hale M. Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clinl Pharmacol 36 (1996) 315-324
33. Shaw L.M., Holt D.W., Oellerich M., Meiser B., and van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 23 (2001) 305-315
34. Shaw L.M., Korecka M., Venkataramanan R., Goldberg L., Bloom R., and Brayman K.L. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 3 (2003) 534-542
35. Shaw L.M., Mick R., Nowak I., Korecka M., and Brayman K.L. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 38 (1998) 268-275
36. Kagaya H., Miura M., Satoh S., et al. No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. J Clin Pharmacy Therapeut 33 (2008) 193-201
37. van Gelder T., and Shaw L.M. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 80 (2005) S244-253
38. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
39. Arns W., Cibrik D.M., Walker R.G., et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 82 (2006) 1004-1012
40. Gregoor P.J., de Sevaux R.G., Hene R.J., et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 68 (1999) 1603-1606
41. Shaw L.M., Nawrocki A., Korecka M., Solari S., and Kang J. Using established immunosuppressant therapy effectively: lessons from the measurement of mycophenolic acid plasma concentrations. Ther Drug Monit 26 (2004) 347-351
42. Rea R.S., Capitano B., Bies R., Bigos K.L., Smith R., and Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 30 (2008) 674-681
43. Trager K., DeBacker D., and Radermacher P. Metabolic alterations in sepsis and vasoactive drug-related metabolic effects. Curr Opin Crit Care 9 (2003) 271-278